The U.S. FDA approved Pfizer Inc's menopause drug Duavee, which the drugmaker hopes will reduce hot flashes and prevent postmenopausal Osteoporosis.
DUAVEE is the first and only therapy to pair conjugated estrogens with an estrogen agonist/antagonist. DUAVEE uses bazedoxifene - instead of a progestin - to help protect the uterine lining against hyperplasia that may result from estrogen-alone treatment. Pfizer anticipates that DUAVEE will be available in the U.S. in the first quarter of 2014. Read more